Second malignancies following pure seminoma

Area of Science:

• Oncology
• Cancer Epidemiology
• Medical Treatment Outcomes

Background:

• Testicular seminoma is a significant cancer diagnosis.
• Understanding long-term risks after treatment is crucial for patient management.
• Previous studies suggest potential links between testicular cancer treatment and secondary malignancies.

Purpose of the Study:

• To investigate the incidence and risk of second malignancies in patients treated for pure testicular seminoma.
• To identify potential adverse late effects of treatment for testicular cancer.
• To assess the significance of second cancers during patient follow-up.

Main Methods:

• A multicentric study observed 839 consecutive patients with pure testicular seminoma.
• Median follow-up was 3.9 years; patients with prior malignancies were excluded.
• Treatment modalities included radiotherapy (758 patients), chemotherapy (76 patients), and surveillance (5 patients).

Main Results:

• Twenty-two second cancers were recorded, including 13 contralateral testicular tumors and 9 extratesticular malignancies.
• The overall risk of a second cancer was significantly increased (RR = 4.8).
• A markedly higher risk was observed for subsequent testicular tumors (RR = 44.8) and renal cell cancer (RR = 12.5).

Conclusions:

• The study confirms an elevated risk of second testicular germ cell cancers post-treatment.
• A small but significant increase in non-testicular second cancers, including renal cell cancer, was noted.
• Non-treatment-related factors, such as genetic predisposition, may contribute to second tumor development, necessitating ongoing surveillance.